Status:
RECRUITING
Immunological Biomarkers in Tuberculosis Management
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Tuberculosis
Tuberculosis Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tuberculosis (TB) is the leading cause of death by infectious disease in the world, responsible for 1.6 million deaths in 2017. The treatment of active TB requires at least a 6-month combined antibiot...
Eligibility Criteria
Inclusion
- Adult ≥ 18 year-old
- Patients having given written consent
- Patients accepting a follow up ≥ 6 months
- Proven active tuberculosis (positive direct examination and/or PCR)
- Latent tuberculosis infection assessed by positive IGRA
Exclusion
- Malignant solid tumor
- Malignant hemopathy
- Solid organ transplantation or hematopoietic stem cell transplantation
- Immunosuppressive treatments (i.e. biologics, calcineurin inhibitors, corticosteroids)
- Auto-inflammatory disease
- Chronic liver diseases
- Chronic infection with HIV, HCV (hepatitis C virus) or HBV (hepatitis B virus)
- Antimycobacterial treatment initiated \> 7 days
- Pregnancy or breastfeeding
- Refusal to participate to the study
- Persons deprived of their liberty by judicial or administrative decision
- Protected adults
- Patients not affiliated to health-care social security
- The homeless
Key Trial Info
Start Date :
September 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 10 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04271397
Start Date
September 30 2019
End Date
October 10 2026
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses - Hôpital de la Croix Rousse - Hospices Civils de Lyon
Lyon, France, 69004